230 related articles for article (PubMed ID: 199393)
21. Transient myasthenia of the newborn. Clinical and electromyographic studies.
Wise GA; McQuillen MP
Trans Am Neurol Assoc; 1969; 94():100-5. PubMed ID: 4313956
[No Abstract] [Full Text] [Related]
22. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis.
Breyer-Pfaff U; Maier U; Brinkmann AM; Schumm F
Clin Pharmacol Ther; 1985 May; 37(5):495-501. PubMed ID: 3987173
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
24. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
[No Abstract] [Full Text] [Related]
25. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
26. [On the treatment of myasthenia].
Delwaide JP
Rev Med Liege; 1968 Sep; 23(18):552-7. PubMed ID: 4316587
[No Abstract] [Full Text] [Related]
27. Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Riggs JE
Clin Neuropharmacol; 1982; 5(3):277-92. PubMed ID: 6288236
[No Abstract] [Full Text] [Related]
28. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
Chirapapaisan N; Tanormrod S; Chuenkongkaew W
Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
[TBL] [Abstract][Full Text] [Related]
29. Renal clearance of pyridostigmine in patients with myasthenia gravis.
Chan K; Calvey TN
Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
[TBL] [Abstract][Full Text] [Related]
30. The diagnosis and management of myasthenia gravis.
Walsh JC
Med J Aust; 1974 Jun; 1(25):997-1001. PubMed ID: 4369281
[No Abstract] [Full Text] [Related]
31. [Therapy of myasthenia gravis with cholinesterase inhibitors--principles and pharmacologic monitoring].
Henze T
Fortschr Neurol Psychiatr; 1996 Mar; 64(3):110-21. PubMed ID: 8900891
[TBL] [Abstract][Full Text] [Related]
32. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
33. Acute effects of verapamil on neuromuscular transmission in patients with myasthenia gravis.
Lee SC; Ho ST
Proc Natl Sci Counc Repub China B; 1987 Jul; 11(3):307-12. PubMed ID: 2827211
[TBL] [Abstract][Full Text] [Related]
34. Malabsorption of pyridostigmine in patients with myasthenia gravis.
Cohan SL; Dretchen KL; Neal A
Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
[TBL] [Abstract][Full Text] [Related]
35. Treatment of myasthenia--I.
Br Med J; 1971 Apr; 2(5754):160-2. PubMed ID: 4325739
[No Abstract] [Full Text] [Related]
36. Topical therapy for oropharyngeal symptoms of myasthenia gravis.
Dooley JM; Goulden KJ; Gatien JG; Gibson EJ; Brown BS
Ann Neurol; 1986 Feb; 19(2):192-4. PubMed ID: 3963762
[TBL] [Abstract][Full Text] [Related]
37. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man.
Davison SC; Hyman N; Prentis RA; Dehghan A; Chan K
Methods Find Exp Clin Pharmacol; 1980 Apr; 2(2):77-82. PubMed ID: 7339332
[TBL] [Abstract][Full Text] [Related]
38. Single fibre EMG in juvenile myasthenia gravis.
Stalberg E; Hansson O
Neuropadiatrie; 1973 Jan; 4(1):20-9. PubMed ID: 4349293
[No Abstract] [Full Text] [Related]
39. Effect of pyridostigmine bromide on serum bromide concentration and the anion gap.
Faradji-Hazan V; Oster JR; Fedeman DG; Clerch AR; Perez GO
J Am Soc Nephrol; 1991 Mar; 1(9):1123-5. PubMed ID: 1912410
[No Abstract] [Full Text] [Related]
40. The pharmacokinetics of pyridostigmine.
Cohan SL; Pohlmann JL; Mikszewski J; O'Doherty DS
Neurology; 1976 Jun; 26(6 PT 1):536-9. PubMed ID: 945494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
